City of Hope

Site:	City of Hope	Go to their website
Address:	1500 E. Duarte Road
City:	Duarte
State:	CA
Zip:	91010
Country:	USA

13 trials at this site

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
			Active
1/2	[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)	Recruiting	Active	neoBOMB1	NCT03872778
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Active	INBRX-109 + Temozolomide	NCT03715933
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
2	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Ongoing, but not recruiting	Closed	Sorafenib (Nexavar, BAY 43-9006)	NCT00265798
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors	Ongoing, but not recruiting	Closed	AMG 479 + AMG 655	NCT00819169
2	MEK Inhibitor AZD6244 With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	Ongoing, but not recruiting	Closed	AZD6244 plus Temsirolimus	NCT01206140
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915